本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600521 证券简称：华海药业 公告编号：临 2025-122 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于"华海转债"可选择回售的第一次提示性公告 浙江华海药业股份有限公司（以下简称"公司"）的股票自 2025 年 11 月 2 日 至 2025 年 12 月 12 日连续 30 个交易日收盘价格低于公司可转换公司债券（以下 简称"华海转债"）当期转股价格的 70%。根据《浙江华海药业股份有限公司公开 发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的约定，可转债 回售条款生效。 现依据《上市公司证券发行管理办法》《可转换公司债券管理办法》《上海证 券交易所股票上市规则》和《募集说明书》等有关规定，就回售有关事项向全体 "华海转债"持有人公告如下： 一、回售条款 1 / 3 回售价格：100.30 元人民币/张（含当期利息、含税） 回售期：2025 年 12 月 22 日至 2025 年 12 月 26 ...

Core Points - The company announces the option for holders of "Huahai Convertible Bonds" to sell back their bonds at a price of 100.30 RMB per bond, including accrued interest and tax [2][4] - The bondholders have the right to choose whether to exercise this option, and the buyback is not mandatory [2][7] - The buyback conditions are triggered if the company's stock price remains below 70% of the bond's conversion price for 30 consecutive trading days [2][3] Buyback Terms - The buyback period is set from December 22, 2025, to December 26, 2025, with funds to be disbursed on December 31, 2025 [4][10] - During the buyback period, the "Huahai Convertible Bonds" will stop being convertible into shares [4][12] - The calculation for the buyback price includes accrued interest, which for the sixth year is approximately 0.30 RMB per bond, leading to a total buyback price of 100.30 RMB [6][13] Buyback Procedures - Bondholders must submit their buyback requests through the Shanghai Stock Exchange trading system during the specified buyback period [8][9] - If a buyback request is not successful on the first day, bondholders can continue to submit requests on subsequent days within the buyback period [9] - The company will announce the results of the buyback and its impact on the company after the buyback period ends [11]

浙江华海药业股份有限公司 关于"华海转债"可选择回售的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因回售期间"华海转债"停止转股,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 110076 | 华海转债 | 可转债转股停牌 | 2025/12/22 | | 2025/12/26 | 2025/12/29 | 浙江华海药业股份有限公司（以下简称"公司"）的股票自 2025 年 11 月 2 日 至 2025 年 12 月 12 日连续 30 个交易日收盘价格低于公司可转换公司债券（以下 简称"华海转债"）当期转股价格的 70%。根据《浙江华海药业股份有限公司公开 1 / 4 回售价格：100.30 元人民币/张（含当期利息、含税） 回售期：2025 年 12 月 22 日至 2025 年 12 月 26 日 回售资金发放 ...

关于浙江华海药业股份有限公司 可转换公司债券回售有关事项的核查意见 浙商证券股份有限公司（以下简称"保荐机构"）作为浙江华海药业股份有 限公司（以下简称"华海药业"或"公司"）2020年公开发行可转换公司债券的 保荐机构，根据《可转换公司债券管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第12号——可转换公司债券》等有关规 定，对华海药业可转换公司债券（以下简称"华海转债"）回售有关事项进行了 审慎核查，并出具核查意见如下： 一、华海转债发行上市情况 浙商证券股份有限公司 经中国证券监督管理委员会证监许可[2020]2261 号文《关于核准浙江华海药 业股份有限公司公开发行可转换公司债券的批复》的核准，华海药业已公开发行 1,842.60 万张可转换公司债券，每张面值 100 元。本次发行募集资金总额为 184,260.00 万元，扣除发行费用 2,089.55 万元（不含税），实际募集资金净额为 182,170.45 万元。 经上海证券交易所自律监管决定书[2020]376 号文同意，公司 184,260.00 万 元可转换公司债券已于 2020 年 11 月 25 日在上海 ...

www.hczq.com 证券研究报告 | 医药生物 | 2025年12月13日 华创医药投资观点&研究专题周周谈 · 第154期 2025Q3实体药店市场分析 本周专题联系人：高初蕾 华创医药团队： | 首席分析师 | 郑辰 | | 执业编号：S0360520110002 | 邮箱：zhengchen@hcyjs.com | | --- | --- | --- | --- | --- | | 联席首席分析师 | | 刘浩 | 执业编号：S0360520120002 | 邮箱：liuhao@hcyjs.com | | 医疗器械组组长 | | 李婵娟 | 执业编号：S0360520110004 | 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 | | 高初蕾 | 执业编号：S0360524070002 | 邮箱：gaochulei@hcyjs.com | | 分析师 | 王宏雨 | | 执业编号：S0360523080006 | 邮箱：wanghongyu@hcyjs.com | | 分析师 | 朱珂琛 | | 执业编号：S0360524070007 | 邮箱：zhukechen@h ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [1][10]. Core Insights - The company is positioned to benefit from its integrated raw material and formulation strategy, which is expected to drive growth in the coming years [6][9]. - The company is transitioning towards innovation, focusing on self-developed biological drugs in the fields of oncology and autoimmune diseases, with a robust pipeline of projects [9][65]. - The financial forecast indicates a recovery in revenue and profit margins, with significant growth expected from innovative drug approvals [10][26]. Summary by Sections 1. Integrated Raw Material and Formulation Layout - The company has established itself as a leading pharmaceutical manufacturer in China, with a strong focus on both raw materials and formulations [20][23]. - The company has faced pricing pressures in raw materials and formulations but is expected to see a recovery in performance starting in 2024 [24][25]. 2. Dual-Driven Growth from Raw Materials and Formulations - The raw material business remains stable, with a diverse product lineup and a strong global sales network [41][43]. - The formulation segment has seen rapid growth, particularly after benefiting from national procurement policies, with a compound annual growth rate (CAGR) of 24.4% from 2012 to 2024 [59][61]. 3. Focus on Biological New Drugs - The company is actively developing innovative drugs, with over 20 projects in the pipeline, including 12 that have entered clinical trials [65][66]. - Key projects include HB0034, which is nearing commercialization, and HB0017, which has shown promising results in clinical trials for psoriasis and ankylosing spondylitis [69][71]. 4. Financial Forecast and Valuation Analysis - Revenue projections for 2025-2027 are estimated at 86.32 billion, 94.13 billion, and 102.82 billion respectively, with corresponding profit growth rates expected to recover significantly by 2026 [10][26]. - The target market capitalization is set at 344 billion, indicating a potential upside of 30.04% based on industry average price-to-earnings ratios [10][26].

Core Viewpoint - Ganli Pharmaceutical Co., Ltd. has received approval for clinical trials of its biosimilar drug GLR1044, targeting a significant market for atopic dermatitis, which has a global annual sales potential of €13.072 billion [2][4] Group 1: Clinical Development and Market Position - GLR1044 is a biosimilar of Dupixent (dupilumab) and aims to enter the atopic dermatitis market, which has approximately 204 million global patients, with an estimated 75 million patients in China by 2025 [2][4] - The drug has only received clinical trial approval and has not yet begun patient enrollment, with a projected clinical trial timeline of 3 to 5 years [3][4] - Competitors such as Qilu Pharmaceutical and Innovent Biologics have advanced clinical trials for similar products, putting Ganli at a disadvantage as a "follower" in the market [3][4] Group 2: Financial Performance and Challenges - Ganli's revenue for the first three quarters of 2025 was CNY 3.047 billion, with a net profit of CNY 818 million, indicating a recovery after previous performance issues [3] - However, the company reported a significant decline in revenue and profit in Q3 2025, with total revenue of CNY 980 million, down 9.4% from Q2, and a net profit decrease of 26% [7] - The core product, insulin glargine, has seen a drop in sales volume and price, leading to concerns about maintaining profitability [8][10] Group 3: Operational and Financial Risks - The company's accounts receivable increased significantly, reaching CNY 530 million, a 147.86% rise compared to the previous year, indicating potential credit policy relaxation [11][13] - High inventory levels of CNY 1.125 billion, which account for approximately 9.3% of total assets, pose risks of depreciation due to market changes or technological updates [15][16] - The slow growth of cash flow compared to net profit raises concerns about the company's operational efficiency and financial health [15][16]

Group 1 - The report highlights a significant divergence in the performance of various sub-sectors within the pharmaceutical industry in 2025, with the CXO and innovative drug-related sectors showing substantial growth, while the medical service sector is expected to gradually recover in 2026 due to a low base effect from 2025 [2][6][58] - The overall performance of the A-share market was positive in 2025, with the pharmaceutical and biological sector ranking 10th with a growth of 34.95%, while the CXO sector led with a growth of 58.71% [6][15] - The report emphasizes the importance of "product-driven" companies, which are expected to enter a profitability cycle as they recover from the impacts of centralized procurement and increase their R&D investments [2][29] Group 2 - The innovative drug sector is projected to continue its upward trend, with business development (BD) opportunities abroad being a key focus, indicating the global competitiveness of Chinese innovative drugs [30][34] - The medical device sector is also expected to follow a similar recovery path as innovative drugs, with increasing R&D investments and a growing number of approved innovative medical devices [43][45] - The medical service sector, despite facing short-term pressures, is anticipated to gradually recover in 2026, supported by an aging population and increasing demand for healthcare services [58] Group 3 - The report suggests specific companies to watch in various sectors, including medical devices (e.g., Sanyou Medical, Aikang Medical), innovative drugs (e.g., Innovent Biologics, Kintor Pharmaceutical), and medical services (e.g., Aier Eye Hospital, Tongce Medical) [2][29] - The report notes that the pharmaceutical sector's overall valuation remains at a historical low, with a price-to-earnings ratio of 30.82 times as of October 31, 2025, indicating potential for upward adjustment [19][20] - The report highlights the importance of key product advancements and performance realization in the innovative drug sector, particularly for products like PD-1/VEGF, which have shown promising clinical data and significant market interest [39][40]

Core Insights - Indian pharmaceutical companies have made significant inroads into the Chinese market, winning multiple bids in the latest national drug procurement round, with prices drastically lower than original branded drugs, indicating a new competitive phase in the market [1][2] - The entry of Indian generics is seen as a major challenge for domestic Chinese generic drug manufacturers, who face both internal and external pressures [1][2] Group 1: Indian Pharmaceutical Companies' Market Entry - Indian companies like Hetero Labs, Cipla, Annora Pharma, and Natco Pharma have collectively won bids for seven drug varieties, marking a record for Indian firms in China's national procurement [1] - Hetero Labs' bid price of 0.215 yuan per tablet is significantly lower than AstraZeneca's original drug price of 4.36 yuan, showcasing the competitive pricing strategy of Indian generics [1] - Indian pharmaceutical firms have prepared extensively for the Chinese market, with many holding multiple registration certificates and having passed consistency evaluations for generics [2] Group 2: Competitive Advantages of Indian Generics - Indian companies benefit from lower production costs, with labor costs being 1/2 to 1/3 of those in China, and significantly lower costs for bioequivalence testing [2] - The production capacity utilization of Indian firms is around 50%, allowing them to offer competitive pricing due to excess capacity [2] - India has become the largest exporter of generics globally, supplying 20% of the world's generics and meeting 40% of the U.S. demand for generics [3] Group 3: Challenges for Chinese Generic Drug Companies - Despite having a large number of pharmaceutical companies, China struggles with quality issues, with many generics failing to meet the efficacy of original drugs [5] - Chinese generic drug companies face significant challenges from price pressures due to national procurement policies and the potential market entry of Indian generics [6] - Companies like Huahai Pharmaceutical and Kelun Pharmaceutical are already experiencing revenue declines and margin pressures due to these competitive dynamics [6] Group 4: Strategies for Chinese Pharmaceutical Companies - Chinese firms are encouraged to enhance R&D investments, focusing on complex formulations and first-generic drugs to differentiate themselves [7] - Expanding into international markets is another strategy, with companies like Ganli Pharmaceutical successfully securing large contracts in Brazil [7] - Smaller companies are advised to specialize in niche areas such as rare diseases and high-tech generics to avoid direct competition with Indian firms [7] Conclusion - The competition in the pharmaceutical market is shifting from national origin to quality, with Indian generics leveraging their scale and cost advantages [8] - The ongoing competition may lead to significant transformations within the industry, with some companies thriving while others may exit the market [8]

Core Insights - Chinese innovative pharmaceutical companies are transforming from participants in global biotechnology transactions to dominant players, leveraging significant R&D and cost advantages [1][2] - The role of these companies has shifted from being technology importers to important exporters, with License-out transactions becoming a key growth driver [1][3] Group 1: Market Position and Trends - Chinese pharmaceutical companies account for approximately 30% of the global total in business development (BD) transactions [2] - Domestic companies are actively positioning themselves in innovative drug R&D, characterized by a "fast, good, and cost-effective" approach [2] - The R&D pipeline of domestic companies has become a crucial source for overseas firms seeking to introduce new products [2] Group 2: Revenue Sources and Transaction Dynamics - BD revenue has become a significant income source for domestic innovative drug companies, with a notable shift from License-in to License-out transactions since 2021 [3] - The proportion of License-out transactions in the total BD transactions has increased from 45% in 2021 to 91% in 2024 [3] - Internationalization and expansion into overseas markets are now vital for revenue growth among domestic innovative drug companies [3] Group 3: Research Focus and Investment Recommendations - The small nucleic acid drug market is experiencing robust growth, with significant commercial, clinical, and BD transaction activity [4] - Multinational corporations (MNCs) continue to rely heavily on China for key supply chain components, particularly in raw materials and intermediates [4] - Investment recommendations include various innovative drug companies and raw material suppliers, highlighting a diverse range of potential opportunities in the sector [4]